部份中文丙酸氟替卡松/富马酸福莫特罗资料（仅供参考）
新的用于哮喘的维持治疗的组合疗法—flutiform（丙酸氟替卡松/富马酸福莫特罗）获批上市。
Flutiform由吸入皮质类固醇（ICS）氟替卡松（fluticasone）与长效β2-受体激动剂（LABA）福莫特罗（formoterol）组成，通过一个单一的气雾吸入器给药，是目前第一个该组合的药物，该组合治疗方法
产品描述
flutiform 50mcg/5mcg，125mcg/5mcg和250mcg/10mcg固定剂量组合的丙酸氟替卡松和富马酸福莫特罗（flutiform吸入器）是组成。
•治疗哮喘，使用相结合的制品（安inhaled corticosteroid速效β2受体激动剂和一个长）是appr不恰当的：
•为患者充分控与inhaled corticosteroids和AS要求我inhaled短- 2激动剂的作用。
•为患者或已经充分控在安inhaled corticosteroid都和一个长2受体激动剂的作用。flutiform吸入器是显示在成人和青少年年龄12岁及以上 。

Product Description
flutiform 50mcg/5mcg, 125mcg/5mcg and 250mcg/10mcg fixed-dose combinations of fluticasone propionate and formoterol fumarate (Flutiform inhaler)are indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting beta2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting
2 agonist. Or • For patients already adequately controlled on both an inhaled corticosteroid and a long-acting
2 agonist. Flutiform inhalers are indicated in adults and adolescents aged 12 years and above.